Cargando…
Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
PURPOSE: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal de...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883142/ https://www.ncbi.nlm.nih.gov/pubmed/36718434 http://dx.doi.org/10.1016/j.ajoc.2022.101789 |
_version_ | 1784879443217481728 |
---|---|
author | El Wardani, Mohamad de Smet, Marc D. |
author_facet | El Wardani, Mohamad de Smet, Marc D. |
author_sort | El Wardani, Mohamad |
collection | PubMed |
description | PURPOSE: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable. CONCLUSIONS AND IMPORTANCE: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery. |
format | Online Article Text |
id | pubmed-9883142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-98831422023-01-29 Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment El Wardani, Mohamad de Smet, Marc D. Am J Ophthalmol Case Rep Case Report PURPOSE: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable. CONCLUSIONS AND IMPORTANCE: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery. Elsevier 2022-12-31 /pmc/articles/PMC9883142/ /pubmed/36718434 http://dx.doi.org/10.1016/j.ajoc.2022.101789 Text en © 2022 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report El Wardani, Mohamad de Smet, Marc D. Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
title | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
title_full | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
title_fullStr | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
title_full_unstemmed | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
title_short | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
title_sort | mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883142/ https://www.ncbi.nlm.nih.gov/pubmed/36718434 http://dx.doi.org/10.1016/j.ajoc.2022.101789 |
work_keys_str_mv | AT elwardanimohamad mineralocorticoidreceptorantagonistsasapotentialtreatmentoptioninpersistentsubretinalfluidfollowingtherepairofarhegmatogenousretinaldetachment AT desmetmarcd mineralocorticoidreceptorantagonistsasapotentialtreatmentoptioninpersistentsubretinalfluidfollowingtherepairofarhegmatogenousretinaldetachment |